Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α‐glucosidase, α‐amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation
Drug Development Research · 2024-06 · 85 (4)
DOI: 10.1002/ddr.22216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 03.06.2024. Verfasst von Ahmed Ragab und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science (boys), Al-Azhar University, Nasr, Cairo, Egypt. Hauptthemen laut MEDLINE: Quinoxalines, Cholinesterase Inhibitors, Glycoside Hydrolase Inhibitors, alpha-Amylases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
A new series of quinoxaline‐sulfonamide derivatives 3 – 12 were synthesized using fragment‐based drug design by reaction of quinoxaline sulfonyl chloride (QSC) with different amines and hydrazines. The quinoxaline‐sulfonamide derivatives were evaluated for antidiabetic and anti‐Alzheimer's potential against α‐glucosidase, α‐amylase, and acetylcholinesterase enzymes. These derivatives showed good to moderate potency against α‐amylase and α‐glucosidase with inhibitory percentages between 24.34 ± 0.01%–63.09 ± 0.02% and 28.95 ± 0.04%–75.36 ± 0.01%, respectively. Surprisingly, bis ‐sulfonamide quinoxaline derivative 4 revealed the most potent activity with inhibitory percentages of 75.36 ± 0.01% and 63.09 ± 0.02% against α ‐glucosidase and α‐amylase compared to acarbose (IP = 57.79 ± 0.01% and 67.33 ± 0.01%), respectively. Moreover, the quinoxaline derivative 3 exhibited potency as α‐glucosidase and α‐amylase inhibitory with a minute decline from compound 4 and acarbose with inhibitory percentages of 44.93 ± 0.01% and 38.95 ± 0.01%. Additionally, in vitro acetylcholinesterase inhibitory activity for designed derivatives exhibited weak to moderate activity. Still, sulfonamide‐quinoxaline derivative 3 emerged as the most active member with inhibitory percentage of 41.92 ± 0.02% compared with donepezil (IP = 67.27 ± 0.60%). The DFT calculations, docking simulation, target prediction, and ADMET analysis were performed and discussed in detail.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science (boys), Al-Azhar University, Nasr, Cairo, Egypt.
- Department of Chemistry, Faculty of Science and Arts, King Khalid University, Mohail, Assir, Saudi Arabia.
- Biochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, Egypt.
- Department of Chemistry, Faculty of Arts and Science, Northern Border University, Rafha, Saudi Arabia.
ORCID-Profile: Ahmed Ragab, Mohamed A Salem, Yousry A Ammar, Wael M Aboulthana, Moustafa S Abusaif
Zitieren
APA
Ragab, A., Salem, M. A., Ammar, Y. A., Aboulthana, W. M., Helal, M. H., & Abusaif, M. S. (2024). Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α‐glucosidase, α‐amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation. Drug Development Research, 85(4). https://doi.org/10.1002/ddr.22216
Vancouver
Ragab A, Salem MA, Ammar YA, Aboulthana WM, Helal MH, Abusaif MS. Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α‐glucosidase, α‐amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation. Drug Development Research. 2024;85(4). doi:10.1002/ddr.22216
BibTeX
@article{Ragab2024,
author = {Ragab, Ahmed and Salem, Mohamed A and Ammar, Yousry A and Aboulthana, Wael M and Helal, Mohamed H and Abusaif, Moustafa S},
title = {Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α‐glucosidase, α‐amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation},
journal = {Drug Development Research},
year = {2024},
volume = {85},
number = {4},
doi = {10.1002/ddr.22216}
}
EUVIMED